Table 1.
Baseline characteristics of study population
| Groups | |||
|---|---|---|---|
| Control group (n=16) | Intervention group (n=15) | Drop-out group (n=9; 4 IG/5 CG)* | |
| Anthropometric data | |||
| Sex, n (male/female) | 8/8 | 6/9 | 4/5 |
| Age, in years Median (Range) | 63.0 (37-74) | 61 (30-86) | 58.0 (51-72) |
| BMI; Median (Range) | 24.4 (17.1-37.4) | 22.1 (17.4-32.6) | 19.8 (15.7-26.0) |
| Disease specific data | |||
| Tumor site, n (%) | |||
| biliary tract | 6 (37.5%) | 6 (40%) | 0 (0%) |
| pancreas | 10 (62.5%) | 9 (60%) | 9 (100%) |
| Stage, n (%) | |||
| IV | 16 (100%) | 15 (100%) | 9 (100%) |
| Metastases, n (%) | |||
| Yes | 16 (100%) | 15 (100%) | 9 (100%) |
| Site of metastases, n (%) | |||
| Liver | 10 (62%) | 9 (60%) | 8 (89%) |
| Peritoneum | 8 (50%) | 7 (46%) | 4 (56%) |
| Lung | 1 (6%) | 1 (7%) | 2 (22%) |
| Bone | 0 (0%) | 1 (7%) | 1 (11%) |
| Othersa | 4 (25%) | 5 (33%) | 3 (22%) |
| Weight loss past 6 months, n (%) | |||
| No weight loss | 9 (56%) | 5 (33%) | 1 (11%) |
| 0-2% weight loss | 0 (0%) | 3 (20%) | 2 (22%) |
| 2-5% weight loss | 1 (6%) | 2 (13%) | 1 (11%) |
| >5% weight loss | 6 (38%) | 5 (33%) | 5 (56%) |
| Treatment specific data | |||
| Chemotherapy lines at study entry; Median (Range) | 2 (2-6) | 2 (2-5) | 2 (2-4) |
| Chemotherapy cycles prior to inclusion; Median (Range) | 10 (2-54) | 12 (1-34) | 17 (5-24) |
| Starting Chemotherapy at T0 | |||
| Gemcitabine based | 7 (44%) | 9 (60%) | 6 (67%) |
| 5-FU based | 6 (38%) | 6 (40%) | 1 (11%) |
| Nanoliposomal irinotecan based | 3 (19%) | 0 (%) | 2 (22%) |
| Blood sampling (t0) | |||
| C-reactive protein, mg/dl | 2.2. ± 4.6; 0.4 (0-18.3) | 0.8 ± 0.8; 0.5 (0-2.2) | 9.0 ± 8.8; 5.10 (0-24.2) |
| Interleukin 6, pg/ml | 7.3 ± 8.8; 6.8 (0-30.7) | 16.0 ± 34.8; 6.4 (0-140) | 51.1 ± 8.8; 25.9 (0-291) |
| CA 19-9, U/ml | 33645.5 ± 7570.4; 294 (0-28684.4) | 6763.4.1 ± 21786; 176.7. (0-85139.2) | 25334.1 ± 57692.5; 2255.2 (14-176817) |
| Neutrophil/lymphocyte ratio % | 3.53 ± 3.8; 2.1 (0.9-16.1) | 2.3 ± 1.2; 2.1 (0.7-5.5) | 7.4 ± 4.7; 6.9 (2.3-16.8) |
*1 Drop-out of the missing patient (withdrew immediately after inclusion, changed hospital), the patient was not included within the baseline characteristic
aLymph nodes, ovarian